Thrilled to announce the acquisition of @CurevoVaccine by @EliLillyandCo for $1.5B 🚀
Congratulations to Moncef Slaoui, George Simeon and the entire Curevo team for achieving this milestone
investor.lilly.com/news-rele…
Medicxi's investment in Curevo is a reflection of our continued conviction in vaccines and infectious disease as impactful areas in modern medicine.
We are excited to partner with @EliLillyandCo on the development of Curevo's next-generation shingles vaccine, Amezosvatein
1
285
We are proud to announce the acquisition of @centessa by @EliLillyandCo for a total of $7.8B
Congratulations to current CEO Mario Accardi, former CEO Saurabh Saha and the entire Centessa Team
investors.centessa.com/news-…
We are proud to unveil our latest fund Medicxi V
Through this €500M fund we will continue our dedicated support for innovative biotech companies and world-class drug hunters with clear product visions to transform patient care
medicxi.com/news/medicxi-ann…
Delighted to announce that KER-0193, a potential treatment for Fragile X syndrome being developed by Kaerus Bioscience, has been acquired by @Servier for up to $450M
Congratulations to Rob Ring and the entire Kaerus team for this fantastic outcome!
kaerusbio.com/copy-of-2025-5…
1
2
449
Kaerus is an asset-centric company founded by Medicxi, to develop small molecules that target the core pathology in Fragile X Syndrome by restoring aberrant neuronal potassium channel function in these patients
1
284
Thrilled to announce that @medicxi portfolio company Vicebio has entered into an exclusive agreement to be acquired by @sanofi for $1.6B, including an upfront payment of $1.15B 🚀🚀
prnewswire.com/news-releases…
Vicebio was created by @medicxi to develop next-generation vaccines for respiratory viruses, utilising its proprietary Molecular Clamp technology
The lead asset, VXB-241, is a bivalent vaccine targeting RSV and hMPV, currently in Phase 1 clinical development
1
2
708
Partnering with @sanofi will help accelerate clinical development of VXB-241 and next generation products
This is a fantastic outcome for the Vicebio platform and for patients suffering these viral respiratory infections
2
519
In this placebo-controlled study, treatment with vapendavir was well tolerated, led to faster reduction in viral load and a shorter overall course of illness with fewer adverse and severe adverse respiratory events versus placebo
1
214
Congratulations to the Altesa Biosciences team on reporting positive Phase 2 data for vapendavir in a Rhinovirus challenge study in patients with COPD
prnewswire.com/news-releases…
1
2
206
Excited to announce that Medicxi has led Curevo Vaccine’s $110M Series B financing
As part of this financing, Giovanni Mariggi will join the board of directors, alongside vaccine industry leaders Moncef Slaoui and Tal Zaks
endpts.com/curevo-gets-110m-…
1
1
373
Curevo is developing Amezosvatein, to address critical unmet needs in shingles vaccination
In Phase 2, Amezosvatein demonstrated competitive efficacy and potential for superior tolerability versus Shingrix, thanks to Curevo’s proprietary adjuvant technology
2
1
244
Congratulations to Kaerus Bioscience for successfully completing Phase 1 development for KER-0193, a novel BK channel modulator for Fragile X syndrome (FXS)
kaerusbio.com/phase1trial
1
2
461
KER-0193 was safe and well tolerated in 56 healthy volunteers, with positive pharmacodynamic effects confirmed in translationally relevant parameters by pharmaco-EEG
1
194
